The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): Phase I results.
 
Takeshi Kato
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
Expert Testimony - Lilly
Travel, Accommodations, Expenses - Eisai
 
Yoshinori Kagawa
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Eiji Oki
Honoraria - Taiho Pharmaceutical; Takeda
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)
 
Hirofumi Yasui
No Relationships to Disclose
 
Hironaga Satake
No Relationships to Disclose
 
Kazunori Shibuya
Employment - Takeda
 
Koji Oba
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical; Takeda
 
Kensei Yamaguchi
Honoraria - Chugai Pharma; Lilly; Merck; Taiho Pharmaceutical; Takeda
Research Funding - Takeda (Inst)